News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Approves MannKind Corporation (MNKD)'s Much Anticipated Diabetes Therapy Afrezza


6/27/2014 2:29:22 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

(Reuters) - The U.S. Food and Drug Administration said on Friday it has approved MannKind Corp's inhaled insulin device, Afrezza, capping an arduous journey for the company and its octogenarian founder, Alfred Mann.

The FDA said the device offers a new treatment option for patients with Type 1 diabetes.

"Today's approval broadens the options available for delivering mealtime insulin in the overall management of patients with diabetes who require it to control blood sugar levels," Dr. Jean-Marc Guettier, director of the FDA's endocrinology division, said in a statement.

Help employers find you! Check out all the jobs and post your resume.

Read at Reuters
Read at Business Week
Read at Star Tribune
Read at Washington Post

comments powered by Disqus
   
Diabetes

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES